Arrowhead (ARWR) announced that the FDA has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $85 from $80 at H.C. Wainwright
- Arrowhead price target raised to $62 from $42 at BofA
- Arrowhead falls -8.3%
- Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity
- Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials